Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage a...
Saved in:
| Date: | 2013 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2013
|
| Series: | Experimental Oncology |
| Subjects: | |
| Online Access: | http://dspace.nbuv.gov.ua/handle/123456789/145224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Cite this: | Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ. |